Delcath Stock Moves Higher After Hepzato Achieves ORR Of 29.2% Beating Prespecified Threshold In Eye Cancer Study

  • Delcath Systems Inc DCTH has announced top-line preliminary results from the Phase 3 FOCUS trial of Hepzato Kit (melphalan hydrochloride for injection/hepatic delivery system) in patients with liver dominant metastatic ocular melanoma.
  • Based on the preliminary analysis of 87% of enrolled patients, the assessed overall response rate (ORR) of 29.2% in the Intent to Treat population exceeded the predefined success criteria (21.0%) for the primary ORR endpoint.
  • Evaluable patients in the HEPZATO arm showed ORR of 32.9% versus 13.8% for the Best Alternative Care (BAC) arm.
  • The Median Progression-Free Survival for the BAC arm was 9.0 months versus 3.1 months.
  • A Disease Control Rate of 70.9% was observed versus 37.9% for patients in the BAC arm.
  • Duration of Response and Overall Survival is not yet evaluable.
  • In the HEPZATO safety population of 94 patients, 38 patients (40.4%) experienced a treatment-emergent serious adverse event, most commonly were thrombocytopenia (14.9% of patients), neutropenia (10.6% of patients), and leukopenia (4.2% of patients), which were well-manageable.
  • 5% of patients experienced treatment-emergent serious cardiac adverse events.
  • The preliminary results are based on a data cut on March 12 and include 79 treated HEPZATO patients.
  • Price Action: DCTH shares are trading 16.7% higher at $19 in premarket on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneraleye cancer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!